Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

特奈特普酶 医学 溶栓 纤溶剂 优势比 组织纤溶酶原激活剂 冲程(发动机) 单中心 瑞替普酶 内科学 心脏病学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Agnete Teivane,Kristaps Jurjāns,Jānis Vētra,Jekaterina Grigorjeva,Karlis Kupcs,Rytis Masiliūnas,Evija Miglāne
出处
期刊:Medicina-lithuania [MDPI AG]
卷期号:58 (9): 1169-1169
标识
DOI:10.3390/medicina58091169
摘要

Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b-3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4-26) vs. 15 (2-31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b-3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17-0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
长隆完成签到,获得积分10
2秒前
科目三应助迷路问梅采纳,获得10
4秒前
4秒前
5秒前
科目三应助国泰民安采纳,获得10
6秒前
6秒前
8秒前
BACK发布了新的文献求助10
10秒前
Qiis发布了新的文献求助10
11秒前
完美世界应助haoqingyun采纳,获得10
14秒前
17秒前
17秒前
木可完成签到,获得积分10
18秒前
星辰大海应助年轻傲松采纳,获得10
19秒前
有机小喽啰完成签到,获得积分10
19秒前
22秒前
22秒前
23秒前
23秒前
23秒前
eric888应助科研通管家采纳,获得50
25秒前
大个应助科研通管家采纳,获得10
25秒前
ding应助科研通管家采纳,获得10
25秒前
完美世界应助科研通管家采纳,获得10
25秒前
脑洞疼应助科研通管家采纳,获得10
25秒前
eric888应助科研通管家采纳,获得50
25秒前
25秒前
26秒前
三人行发布了新的文献求助10
28秒前
拼搏的冰绿完成签到 ,获得积分10
32秒前
JamesPei应助淡淡智宸采纳,获得10
32秒前
Ava应助Qiis采纳,获得10
32秒前
xcchh发布了新的文献求助10
34秒前
泡泡发布了新的文献求助10
36秒前
36秒前
浩浩发布了新的文献求助30
37秒前
虚心的芝麻完成签到 ,获得积分10
37秒前
38秒前
39秒前
淡淡智宸完成签到,获得积分10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Psychology and Work Today 1400
Operational Bulk Evaporation Duct Model for MORIAH Version 1.2 1200
Variants in Economic Theory 1000
Global Ingredients & Formulations Guide 2014, Hardcover 1000
Research for Social Workers 1000
Signals, Systems, and Signal Processing 880
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5837980
求助须知:如何正确求助?哪些是违规求助? 6128376
关于积分的说明 15600162
捐赠科研通 4956231
什么是DOI,文献DOI怎么找? 2671479
邀请新用户注册赠送积分活动 1616664
关于科研通互助平台的介绍 1571738